spironolactone has been researched along with pf-03882845 in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arhancet, GB; Blinn, JR; Chen, X; Collins, JT; Dietz, JD; Garland, DJ; Heron, MI; Hockerman, SL; Homer, BL; Hu, X; Huang, HC; Long, SA; Mahoney, MW; McGee, KF; Meyers, MJ; Payne, MA; Reitz, DB; Rico, JR; Wendling, JM; Yang, S | 1 |
| Ambler, C; Arhancet, GB; Banker, ME; Banks, T; Boustany-Kari, CM; Cai, C; Casimiro-Garcia, A; Chen, X; Eudy, R; Hepworth, D; Hulford, CA; Jennings, SM; Loria, PM; Meyers, MJ; Petersen, DN; Piotrowski, DW; Raheja, NK; Sammons, M; She, L; Song, K; Vrieze, D; Wei, L | 1 |
2 other study(ies) available for spironolactone and pf-03882845
| Article | Year |
|---|---|
Discovery of (3S,3aR)-2-(3-chloro-4-cyanophenyl)-3-cyclopentyl-3,3a,4,5-tetrahydro-2H-benzo[g]indazole-7-carboxylic acid (PF-3882845), an orally efficacious mineralocorticoid receptor (MR) antagonist for hypertension and nephropathy.
Topics: Animals; Antihypertensive Agents; Blood Pressure; Cell Line, Tumor; Chlorobenzenes; Crystallography, X-Ray; Humans; Hypertension; Indazoles; Indenes; Kidney Diseases; Male; Mineralocorticoid Receptor Antagonists; Models, Molecular; Molecular Conformation; Nitriles; Radioligand Assay; Rats; Rats, Inbred Dahl; Rats, Sprague-Dawley; Stereoisomerism; Structure-Activity Relationship | 2010 |
Identification of (R)-6-(1-(4-cyano-3-methylphenyl)-5-cyclopentyl-4,5-dihydro-1H-pyrazol-3-yl)-2-methoxynicotinic acid, a highly potent and selective nonsteroidal mineralocorticoid receptor antagonist.
Topics: Animals; Drug Discovery; Male; Mineralocorticoid Receptor Antagonists; Molecular Docking Simulation; Nicotinic Acids; Potassium; Pyrazoles; Rats; Rats, Sprague-Dawley; Receptors, Mineralocorticoid; Sodium; Structure-Activity Relationship | 2014 |